Sotatercept rapidly improved cardiogenic shock and respiratory failure in a decompensated PAH patient requiring VA ECMO in an ICU setting.
Does sotatercept improve clinical status in patients with decompensated PAH and acute right ventricular failure requiring VA ECMO?
Sotatercept may be a viable rescue therapy for acute right ventricular failure and cardiogenic shock in decompensated PAH patients requiring VA ECMO.
Absolute Event Rate: 0% vs 0%
ABSTRACT Pulmonary arterial hypertension (PAH) is a rare and progressive disease resulting in increased workload of the right ventricle (RV). Despite advances in therapies, PAH remains highly morbid from a progressive vasculopathy and RV failure. For patients admitted to hospital with RV failure, transplant remains the only option for a select few. Sotatercept, a novel activin signaling inhibitor approved for the treatment of PAH, has demonstrated significant improvement in clinical outcomes across a wide spectrum of disease severity. However, descriptions of its use to treat acute RV failure in an intensive care unit (ICU) setting are limited. We report a case of cardiogenic shock and respiratory failure secondary to decompensated PAH requiring veno‐arterial extracorporeal membrane oxygenation (VA ECMO), with rapid improvement following sotatercept initiation.
Taylor et al. (Thu,) reported a other. Sotatercept rapidly improved cardiogenic shock and respiratory failure in a decompensated PAH patient requiring VA ECMO in an ICU setting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: